Загрузка...
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
Ibrutinib is a Bruton tyrosine kinase inhibitor that is approved by the FDA for the treatment of mantle cell lymphoma and other hematological malignancies. Bruton tyrosine kinases promote platelet aggregation, and, therefore, bleeding is a common side effect of ibrutinib. At least half of patients t...
Сохранить в:
| Опубликовано в: : | Cureus |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Cureus
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7377008/ https://ncbi.nlm.nih.gov/pubmed/32714681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.8743 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|